Research, page-1125

I cut my losses ($200k plus) and have found it prosperous making gains elsewhere since so do not regret this.

I think the real issue has been the over promise which another poster once said a said at a pre IPO meeting he went to the vibe was large US deals were imminent and if you look at the 08/10/2020 release this is when I got in based on the upbeat comments on pages 27 and 28 which did not materialise.

Slide 27 - being told clinical trials are complete when they weren't, or if they thought they were, they weren't.

Slide 28 - Terms like existing partnerships with some of the most prestigous hopsitals, KOL's have a strong understanding, platform already in use, 2 noted as paying revenue, significant revenue potential in the immediate term... 2 + years on and basicaliy no revenue from any of these 8 hospitals.

Granted this may have been their view and expectations but clearly 2 + years on we can see the expected revenue (or any real revenue) did not come to fruition and it would have contriburted to over inflating the share price and luring in investors like me and others here under an illusion. If they floated with none of these claims which turned out to be hot air it prob never trades above $1, plus Covid was going on to push it also.

I regret not selling out when after a few months nothing was announced and we were being told to do more clinical trials at these hospitals. I was questioning the company who had no answers and were more or less silent so also a warning sign. Same as when I questioned the 18/12/2020 release which said rollout would happen early in 2021 then each 4C went by with no revenue and no update even. See comments below, yet here we are with iMed only finally rolled out a year on and then the Sep 2022 qtr revenue blanks and we are told it is payment timing even though they have been scanning for 9 months? They never tell us numbers of scnas? Who could really trust this management if we are all being honest to ourselves?

'The scan was successfully completed in Victoria and marks the first commercial use of XV LVAS as the
Company begins to roll out its infrastructure nationally. Installation of XV LVAS is anticipated in hospitals
and imaging centres in Victoria as well as other states from early 2021.'

I do not buy the legal liability and crap about needing doctors to understand it, it is quite easy to look and see, my doubts would be doctors don't actually see it picking up fine tumors, it requires fluroscopy X-Ray I believe not regular X-Ray which is higehr radiation and another thing they don't make clear. I researched into how doctors read X-Rays and also did not see many cases where the 4DX would help. It may have applications for certain ongoing patients but how big is this market? It looks more beneficial to research areas. If it was going to be revolutionary in my view by now we would have seen the uptake of the technology.

I agree long term we may see them make it but as it stands to me management has minimal cfedibility, they have not delivered on their comments/promises, A CR may be needed soon given some of the cash they hold is set aside for the MRFF grant? Burning up $9 mill a quarter so by June 2023 be down to near $20 million and unlikely to be any real revenue based on iMed and how this is going.